Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - ...

1. Faster eschar removal: NexoBrid achieved complete eschar removal in a median time of one day compared to six days with SOC (p 0.001) 2. Reduced wound area excised: The mean percentage of wound area ...

These results reinforce NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a ...

Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of MediWound in a research ...

MediWound (NASDAQ:MDWD – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a report issued on Friday. Other research analysts have also issued reports about the company.

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep ... for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx ...

Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its ...

If there are large wound care companies that you don’t see in this slide ... The first one on the left is NexoBrid. NexoBrid is a drug for eschar removal for severe burns. In order to remove SCAR in ...

Typical lesions progress from red or gray macules or papules, to red or gray macules or papules with a central eschar or ulceration ... Panafil® was applied to the wound to loosen the necrotic ...